Table 2.

Percentage of mice that did not develop a tumor after a rechallenge

	DA3 tumorsa			CT-26 tumorsb
Days after rechallenge	4	9	16	7	21	35
DaRT	77 %	27 %	15 %	100 %	88 %	67 %
Inert	62 %	4 %	0 %	78 %	56	34 %
Surgery	65 %	0 %	0 %	100 %	57	43 %
Naïve	69 %	8 %	4 %	0 %	0 %	0 %

DA3 or CT-26 primary tumors were treated by DaRT followed by surgery, inert + surgery or surgery alone. Three weeks after wire insertion, the mice were rechallenged with a tumorigenic dose of tumor cells and tumor development was monitored

^aDA3 rechallenge was injected s.c. to 24–26 animals/group for each treatment

^bCT-26 rechallenge was injected s.c. to 7–9 animals/group for each treatment